Resistance training may curb lean mass loss with tirzepatide
-
By
-
Andrea Surnit
-
November 20, 2026
-
5 min
Clinical Scorecard: Resistance training may curb lean mass loss with tirzepatide
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: Resistance training may curb lean mass loss with tirzepatide |
| Key Mechanisms | In a 40-week trial, supervised resistance exercise reduced loss of DXA-measured lean soft tissue mass and improved bench press, lat pulldown, and knee extension strength during tirzepatide treatment; weight and fat loss were similar between groups. |
| Target Population | Patients or participants described in the source article. |
| Care Setting | Care setting described in the source article. |
Key Highlights
- At week 40, total lean soft tissue mass loss was 3.57 kg with resistance exercise plus tirzepatide and 4.67 kg with tirzepatide alone; the between-group difference was 1.09 kg.
- Appendicular lean soft tissue mass loss was 0.63 kg lower with resistance exercise than with tirzepatide alone.
- Bench press, lat pulldown, and knee extension strength increased in the exercise group and declined in the tirzepatide-only group; all between-group differences were statistically significant.
- Weight loss, fat mass loss, BMI, waist circumference, and measured cardiometabolic changes were similar between groups.
- The trial enrolled 120 participants; 93% completed 40 weeks, and mean adherence to supervised exercise sessions was 91%.
Guideline-Based Recommendations
Diagnosis
Management
- Study authors stated that resistance exercise training should be considered when prescribing incretin mimetics as anti-obesity therapy.
- The tested intervention was progressive, supervised resistance training for approximately 1 hour, 3 times weekly, alongside tirzepatide for 40 weeks.
Monitoring & Follow-up
Risks
- Gastrointestinal adverse events were common in both groups; nausea occurred in 55% of participants, and constipation, diarrhea, and indigestion were reported in approximately 29% to 36%.
- Six serious adverse events occurred; the authors considered none related to tirzepatide or resistance exercise.
- The study used DXA measures of lean soft tissue mass, not direct measures of skeletal muscle mass, and did not establish long-term clinical outcomes.
Patient & Prescribing Data
The T-REx trial included 120 initially sedentary men and postmenopausal women aged 50 to 70 years with obesity or overweight plus at least one weight-related comorbidity. Participants did not have diabetes or cardiovascular disease.
Participants received tirzepatide for 40 weeks, titrated to a maximum of 15 mg weekly as tolerated; 61 were assigned to tirzepatide alone and 59 to tirzepatide plus supervised resistance exercise. Among 111 treatment completers, 78 received the maximum dose.
Clinical Best Practices
- When discussing the trial, distinguish lean soft tissue mass measured by DXA from skeletal muscle mass.
- Explain that resistance exercise was associated with less lean soft tissue mass loss and greater measured strength, while weight and fat loss were comparable between groups.
- Consider the trial's limits when applying its findings: participants were initially sedentary, the exercise was closely supervised, and follow-up lasted 40 weeks.
- Note that the study did not determine whether the observed lean mass differences lead to improved long-term clinical outcomes.
Related Resources & Content
Based on findings from:
Resistance training may curb lean mass loss with tirzepatide
Andrea Surnit. MDSpire News, 2026.
https://news.mdspire.com/internal-medicine/articles/resistance-training-may-curb-lean-mass-loss-with-tirzepatide/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.